糖皮质激素治疗自身免疫性大疱病:国际研究揭示类固醇性肌病特征
这项国际队列研究在2019年2月至2023年7月期间,于澳大利亚、中国、希腊、伊朗、日本、菲律宾、土耳其和美国的疱病门诊,使用糖皮质激素毒性指数(GTI)评估自身免疫性大疱病(AIBD)患者中糖皮质激素性肌病(GIM)的患病率和危险因素。共纳入139例患者,47.5%在 study 期间出现肌无力,累计GC剂量与肌病风险正相关,而平均剂量和治疗 duration 无显著关联。高龄、男性和肥胖使GIM风险增加一倍以上;累计GC剂量低于0.75 mg/kg/day时肌无力较少发生。
要点
- AIBD患者中47.5%出现肌无力,GIM常见。
- 累计GC剂量与肌病风险正相关,平均剂量和疗程无关。
- 高龄、男性、肥胖使GIM风险增加一倍以上。
核心结论
- GIM是AIBD患者接受GC治疗的常见副作用,累计GC剂量是关键风险因素。
研究设计与样本
- 国际队列研究,在8个国家疱病门诊纳入139例AIBD患者,2019年2月至2023年7月,使用GTI工具评估。
主要发现
- 139例患者中发生132次肌病事件,47.5%患者出现肌无力。
- 累计GC剂量与肌病风险正相关,平均剂量和治疗时长无显著关联。
- 高龄、男性、肥胖使GIM风险增加一倍以上。
关键数值与推荐
- 累计GC剂量低于0.75 mg/kg/day时肌无力较少发生。
临床怎么用
- 临床应监测AIBD患者GC治疗期间的肌无力,尤其高龄、男性、肥胖者,控制累计GC剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with autoimmune blistering diseases (AIBDs) are often exposed to chronic glucocorticoid (GC) treatment with many side effects. Glucocorticoid-induced myopathy (GIM) is a well-established side effect, which particularly affects the proximal muscles. The Glucocorticoid Toxicity Index (GTI) is a validated global assessment tool which quantifies GC toxicity over time. OBJECTIVES: This study marks the first study which analyses GIM in patients with AIBDs. The objectives of this study were to utilize the GTI to investigate the nature and prevalence of GIM in AIBD patients and explore potential risk factors. METHODS: This international cohort study was conducted in blistering disease clinics across Australia, China, Greece, Iran, Japan, the Philippines, Turkey and the United States of America between February 2019 and July 2023. The GTI tool was completed by a medical practitioner at each patient visit. Data related to glucocorticoid toxicity were entered into the Steritas GTI 2.0 to generate an aggregate improvement and cumulative worsening score at each visit. RESULTS: The study included 139 patients. There were 132 episodes of myopathy, and 47.5% of patients developed muscle weakness at some point during the study period. Cumulative GC dose correlated positively with myopathy risk, while average dose and treatment duration were not significant. Older age, male gender and obesity more than doubled the likelihood of developing GIM. CONCLUSIONS: GIM is a common side effect experienced by AIBD patients on GC treatment. Muscle weakness is less likely to occur if cumulative GC dose is less than 0.75 mg/kg/day. Studies of exercise programs to mitigate myopathy and newer alternative treatments to reduce cumulative GC dose should be considered.
引用
- He A, Koszegi B, Uzun S, et al. Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy. J Eur Acad Dermatol Venereol. 2024. PMID: 38818849. doi:10.1111/jdv.20149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。